Health Care & Life Sciences » Pharmaceuticals » Top pharmaceutical drugs | Top anti-viral products by revenue worldwide 2024 forecast

Leading five global anti-viral products by revenue 2017 and 2024

Top 5 global anti-viral products based on revenue in 2017 and 2024 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data shows the top 5 global anti-viral products base on their revenue worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to generate 3.4 billion USD in revenues by 2024.

Biktarvy (Gilead Sciences) 6103
Triumeq (GlaxoSmithKline) 3172 4731
Genvoya (Gilead Sciences + Torii) 3731 3402
Mavyret (AbbVie) 500 2871
Tivicay (GlaxoSmithKline) 1810 2708

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.